Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
無料サンプル 1 mg | |||||
1 mg | 在庫あり | ¥ 32,000 | |||
5 mg | 在庫あり | ¥ 80,000 | |||
10 mg | 在庫あり | ¥ 129,500 | |||
25 mg | 在庫あり | ¥ 204,500 | |||
50 mg | 在庫あり | ¥ 282,500 | |||
100 mg | 在庫あり | ¥ 383,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 102,500 |
説明 | Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities. |
別名 | LY293111, VML295 |
分子量 | 544.61 |
分子式 | C33H33FO6 |
CAS No. | 161172-51-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (183.62 mM), sonification is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Etalocib 161172-51-6 Apoptosis GPCR/G Protein Immunology/Inflammation LTR Leukotriene Receptor antiinflammatory VML 295 inhibit VML-295 LY-293111 LY293111 Pulmonary LY 293111 Inhibitor VML295 asthma bronchiectasis inhibitor